Systematic synergy modeling: understanding drug synergy from a systems biology perspective by Di Chen et al.
REVIEW Open Access
Systematic synergy modeling: understanding
drug synergy from a systems biology perspective
Di Chen1, Xi Liu1, Yiping Yang1, Hongjun Yang2* and Peng Lu1,2*
Abstract
Owing to drug synergy effects, drug combinations have become a new trend in combating complex diseases like
cancer, HIV and cardiovascular diseases. However, conventional synergy quantification methods often depend on
experimental dose–response data which are quite resource-demanding. In addition, these methods are unable to
interpret the explicit synergy mechanism. In this review, we give representative examples of how systems biology
modeling offers strategies toward better understanding of drug synergy, including the protein-protein interaction
(PPI) network-based methods, pathway dynamic simulations, synergy network motif recognitions, integrative drug
feature calculations, and “omic”-supported analyses. Although partially successful in drug synergy exploration and
interpretation, more efforts should be put on a holistic understanding of drug-disease interactions, considering
integrative pharmacology and toxicology factors. With a comprehensive and deep insight into the mechanism of
drug synergy, systems biology opens a novel avenue for rational design of effective drug combinations.
Introduction
Drug combinations have been widely used in treating
complex diseases such as cancer, HIV and cardiovascular
diseases. For example, cisplatin and sabarubicin are co-
administrated in lung cancer [1], combination of aspirin
and dipyridamole is used to reduce the risk of stroke [2],
and a novel FDA-approved drug combination: StribildTM
[3] will been applied in the HIV-1 treatment. According
to the Drug Combination Database (DCDB) [4], there
have been 330 FDA-approved and 1033 investigational
drug combinations until the second version. With more
and more researches on this new form of therapy, drug
combinations have been proven a promising way to
combat complex diseases [5–9].
The most prominent benefit of a drug combination is
the synergy effect among different drugs, where synergy
means that the overall therapeutic effect of the combin-
ation is greater than the sum of effects caused by indi-
vidual components [10]. In order to discover new
combinations, quantification of drug synergy is one of
the essential works. However, synergy quantification is
not an easy task. Different dose–response methods,
including Loewe additivity [11, 12], Bliss independence
[13], and Chou-Talalay method [14] have been pro-
posed. The main concept of these methods is to find
out whether the observed combination effect or re-
sponse departs from the expected effect, as reviewed in
[10, 15, 16]. The dose–response methods play key roles
in synergy quantification. However, no single method
can describe synergy under all possible conditions. Be-
sides, none of these methods has the overwhelming
superiority under all conditions [10]; different forms of
dose–response methods may even produce different re-
sults [17]. At present, it is still impractical to screen all
possible drug combinations for different diseases. In
addition, these dose–response methods cannot explain
the potential synergy mechanism for drug combina-
tions. Such problems suggest that the identification of
synergistic drug combinations remains a non-trivial and
challenging task. As “network-based drug discovery is
taking the pharmaceutical industry into a new age”
[18], systems biology and computational technologies
have provided a powerful tool for multi-target drug
discovery [19–21]. Consequently, systems biology has
become a compensative way to predict novel synergistic
drug combinations and to illustrate underlying mechan-
ism. Such predictions can help accelerate the generation
of hypotheses on possible synergistic drug combinations
and guide the experimental conductions.
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Systems biology allows us to describe the interactions
among different molecules from a comprehensive network
perspective. Currently, some systems biology approaches
have been applied in drug synergy researches to predict
the complex human body responses to drug combina-
tions, to recognize the specific biological network features
which are more likely to produce synergistic outcomes,
and to illustrate the complicated molecular interactions
which may contribute to synergistic mechanism [22–25].
Understanding the explicit relationships among different
objects involved in drug combinations allows us to appre-
ciate how drugs interact with each other to produce syner-
gistic therapeutic effects.
In the future, systematic synergy modeling will provide
an assistant tool independent of screening data to acceler-
ate the generation of hypotheses and guide the experi-
mental activities. Here we review the current status of this
new field and describe how, in our view, systems biology
models (as classified in Table 1) can help us to develop a
predictive and mechanistic model of drug synergy.
Review
Predicting synergy combinations based on the PPI network
The traditional “one drug, one target” therapeutic mode
can only yield limited effects on complex diseases, be-
cause these diseases are mostly controlled by complex
biological networks which involve compensative bio-
logical processes [26, 27]. On the contrary, drug combi-
nations, with multiple targets belonging to interlinked
processes, can combat the systematic pathological states
through the cooperative mechanism. Researchers have
recently applied network-based systems biology ap-
proaches to predict potential synergistic drug combina-
tions, as well as to reveal the synergy mechanism from
the perspective of biological molecular network. Most of
such researches based on the hypothesis that synergistic
drugs tend to have effects on targets with distinguishing
network topological features [28–31].
One of the most frequently used biological molecular
networks is the protein-protein interaction (PPI) network
which is based on intentional physical or functional asso-
ciations between proteins. The PPIs are the core of the
whole interactomics system of any living organism and are
also the foundation of more highly specified networks
such as a disease-specific molecular network. The disease-
specific PPI network often refers to a protein network in
which the proteins are related with one certain disease
[32–34]. Based on a disease-specific PPI network, a heur-
istic synergy score can be calculated based on the topology
connection and centrality of drug targets to predict the
possible synergy degree. Other associated scores can also
be coupled with to adjust the topology-based scores. For
example, two evaluation scores, topology score (TS) and
agent score (AS) were created to evaluate drug synergy for
two drug combination by an algorithm termed NIMS
(network target-based identification of multicomponent
synergy) [28] (as outlined in Fig. 1). The TS was based on
the topology relationship among targets from different
components in the context of a previously defined
disease-specific PPI network. The TS for two drugs will
be high if they target on proteins which are close to
each other on the PPI network and with high network
Table 1 A classification of systematic drug synergy prediction models
Model type Description Inputs Methods Outputs
PPI network-
based models
Evaluate drug synergy based on network
topology relations of targets







Simulate the dynamic changes of pathway and
identify synergy-specific pathway structures





Pathway structures; Network motif
recognition
Synergy-specific







Construct classification models based on various
drug similarities
Drug properties like targets,
structures, indication, et al.
Similarity calculation; Synergistic drug
combinations;





Apply “omic” data to calculate drug associations;
or rebuild the synergy-dependent pathways
Responses to drugs in the
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centralities. The AS was to measure the phenotype
similarity between the corresponding phenotypes of
drugs. This phenotype similarity quantifies the overlap
of their OMIM descriptions and is calculated by a text
mining method. At last, a predictive synergy score was
calculated as the product of TS and AS. Some synergis-
tic ingredients from anti-angiogenic traditional Chinese
medicine were successfully recognized by this score.
Likewise, in the background of a disease-specific PPI
network integrated of different data sources, Vitali et al.
Fig. 1 A schematic example of the PPI network-based synergy score calculation. The calculation strategy in this example was from the method
described in [28]. The green and red triangles represent two different drugs. Each drug is targeting on certain protein targets denoted as circles with
the same color as the corresponding drug. All the targets are mapped into a disease-specific PPI network, in which purple circles are pathological
proteins, while white circles are other high-related proteins, and different proteins are connected by PPIs. Based on the disease-specific PPI network (G),
topology score TS(A, B) can be calculated by the topology connection and centrality for targets of drug A (TA) and targets of drug B (TB), where IP means
a integrative topological parameter calculated by integrating betweenness, closeness and a variant of the eigenvector PageRank through PCA, IPA(i) is
calculated for the target i of drug A and IPB(i) for the target j of drug B, and min(di,j) represents the minimum shortest path from the ith target of drug A to
all targets of drug B. Another agent score (AS), in which Pi,j represents the similarity score between the ith phenotype of drug A and the jth phenotype of
drug B, can also be coupled with to adjust the topology-based score. At last, a synergy score can be calculated by the product of TS and AS
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[29] assigned a score called Topological Score of Drug
Synergy (TSDS) to evaluate the multi-target combin-
ation effects based on the target topological features
including node reachability, global effect and synergistic
effect. This work has been applied to identify novel tar-
gets which may lead to synergistic outcomes for Type 2
Diabetes Mellitus. To cover more knowledge about
drug behavior, Huang et al. [30] proposed another
synergy evaluation tool: “DrugComboRanker”. In this
approach, the synergistic score incorporated topological
relatedness of targets in the signaling network, seman-
tic similarity of gene ontologies, and dissimilarity of the
gene expression profiles of different drugs. The method
was assessed on lung adenocarcinoma and endocrine
receptor positive breast cancer and most of the top-
ranked synergistic combinations were confirmed by lit-
erature reports.
PPI network-based method is an effective and straight-
forward way to elucidate the inter-relationship between a
complex disease and drug interventions. In a generous
way, Wang et al. [31] have indicated that drug combina-
tions tend to target proteins which are closer in the gen-
etic interaction networks comparing against random
combinations. In network-based synergy evaluation, target
acquisition and disease network construction are two
basic steps. By mapping drug targets onto disease-related
molecular networks, it can not only help reveal the mech-
anisms of action for each drug, but also highlight how dif-
ferent drugs in a combination cooperate with each other
to achieve synergy effects. The corresponding topology
relationships of drug targets are of importance for estimat-
ing synergy among combinations. However, it is a fact that
the behavior of a drug is not only determined by its tar-
gets; other factors, like drug side effects, drug-resistance
and other pharmacokinetic characteristics, will also be the
root of drug synergy. Therefore, a more comprehensive
model which is not limited to PPIs should be constructed
to model the complicated interactions involved in the
mechanism of action for drug combination.
Exploring synergy mechanism from the perspective of
pathway
A pathway refers to a series of chemical reactions or mo-
lecular interactions within a cell that generate a specific
product, response or change in the cell [35]. Although the
PPI network-based approaches described above can help
discover potential synergistic drug combinations, path-
ways, which can represent specific parallel, cross-talk or
feedback structures of molecular networks, are even more
powerful for the explanation of synergy mechanism in
more details. Different drugs can have influences on the
same or different pathways, and induce synergy effects
produced by targets aggregating at specific pathway struc-
tures, as revealed in [36]. Modeling the dynamic changes
and network structures of pathways can help improve our
understanding on the potential synergy mechanism for
drug combinations.
Dynamic pathway simulation
Dynamic simulation of specific pathway under drug inter-
ferences can help us understand the dynamic behavior of
drugs, and provide insights into the synergy mechanism of
certain drug combinations. Such pathway simulation
models are often represented in a network form: nodes
stand for concentrations or activity levels of pathway com-
ponents (e.g., gene, protein or metabolite) and edges
reflect the interaction of one node on the time derivative
of another (Fig. 2a). Moreover, dose–response data can be
obtained from the simulation results (Fig. 2b). Based on
these results, synergy can be quantified by traditional
dose–response methods like Bliss independence and
Loewe additivity.
Classical chemical kinetics utilizes ordinary differential
equations (ODE) to describe system dynamics [37–39]. A
system of ordinary differential equations is the most fun-
damental way to quantitatively simulate the dynamic re-
sponse of each individual molecule in a pathway under
different conditions like the interventions of drug combi-
nations [40–43]. Based on a kinetic ODEs model of the
epidermal growth factor receptor (EGFR) signaling path-
way, Araujo et al. [40] simulated the effects of combina-
torial kinase inhibitors and discovered that a simultaneous
inhibition of multiple nodes in a signaling cascade with
small molecule kinase inhibitors will be a new promising
combination strategy for cancer treatment. Modification
of classical kinetic ODE models can improve the ability in
reproducing cellular dynamics. Nelander et al. [41] derived
a non-linear ODE model to capture the important phe-
nomena which cannot be described by simple linear
model, like the epistasis and saturation effects in a cellular
system. Based on this model, the authors can predict the
quantitative outcomes of combinatorial perturbations in
breast cancer cells. Likewise, Miller et al. [43] also utilized
a non-linear ODE model to quantitatively simulate the
dynamic changes of signaling pathways in dedifferentiated
liposarcoma cells. Integrating with the experimental drug
combination screening, the simulation helps to explain
that the synergy of CDK4 and IGF1R inhibitors may
depend on the activity of AKT pathway.
Except for the ODE models, other computational
methods have also been applied in pathway modeling for
drug combination analysis. A modeling framework based
on the modular response analysis (MRA) was developed
to build a simulation model for the EGFR signaling path-
way [44]. The MRA model can quantitatively simulate the
dynamic changes triggered by feedback cycle, feedforward
loop as well as cross talk structures in pathways. Based
on the MRA model, Klinger et al. [44] deduced that
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downstream mutations do not necessarily invalidate up-
stream drug treatment if a suitable downstream inhibitor
were combined. Different researches pay attention to dif-
ferent types of pathway structures. Yan et al. [45] proposed
a mathematical model to simplify the serial and parallel
structures of biological pathways. Besides, Asfar et al. [46]
utilized the network modeling based on the Ingenuity
Pathway Anallysis (IPA) Software which considers the
microarray datasets at different time points to understand
central synergy mechanisms for the combination of
MI219 and oxaliplatin. Sometimes, simulations only based
on the disease-specific pathway are not enough to describe
the drug synergy mechanism, extra pathways which can
indirectly affect the therapeutic process should also be
considered. In the study of Li et al. [47], which aimed to
investigate on the role of immune system response in me-
diating anti-influenza drug synergy, both of the influenza
A virus life cycle pathway and two immune-related path-
ways were simulated by a series of delay differential
equations.
Synergy-specific network motifs in pathways
The above-mentioned pathway simulation models pro-
vide a more concrete way to predict effective drug
combinations. What’s more, they offer tools to discover
which types of structures in pathways are more inclined to
generate drug synergies, thus illustrating the mechanism
of synergy at the pathway level. However, the pathway
simulation models are often hampered by their incom-
pleteness and complexity. To address this problem, re-
duced or abstract network models which can capture key
dynamical properties of a network can be used. These re-
duced models, termed as network motifs, are composed
of same number of elements and are used to describe dis-
tinct connectivity patterns that occur frequently in the
whole network or different pathways [48–50] (Fig. 3). Pre-
vious researches have begun to depict the dynamics of
network motifs by kinetic ODE methods, and describe
how variations in the kinetic parameters affect the human
body responses to drug interventions [50–52]. Different
studies may produce distinctive forms of motifs consider-
ing their specific focuses. In the study of Zhang, et al. [53],
based on ten three-node small network motifs covering
main pathway sub-structures like positive feedback loop,
negative feedback loop, positive auto-regulation, and feed-
forward loop, they recognized which kind of concurrent
variations could act synergistically (or antagonistically) to
alter the responses of the motifs and which type of motifs
Fig. 2 An example of pathway simulation model. a. A network-based pathway simulation model of the EGFR signaling pathway. Circles represent
different components in a pathway. Triangles are drugs. Edges represent the reactions among different elements of the pathway, and the
quantitative dynamic changes for each element can be described by one ODE or other computational models. This pathway network is adapted
from Klinger et al. [44]. b. Dose–response plots. The dose–response curves are based on the pathway simulation results for each individual drug
(a, b) and the drug combination (ab) respectively, where the half maximal inhibitory concentration (IC50) can be utilized to quantitatively assess drug
synergism by dose–response methods like Loewe additivity. If the ratios of two drugs in the combination are both 0.5, an interaction index can be
calculated as: 0:5IC50ABIC50A þ 0:5IC50ABIC50B , where the denominators represent doses of each drug in the combination that yield a half inhibition effect, while
the numerators represent the dose of each drug to produce the same effect when given alone. If this index is larger than one, two drugs are
antagonistic, if it is less than one, the combination is synergistic. For the given example, this index is less than one, so drug A and B are synergistic
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were more likely to lead to synergistic (or antagonistic) re-
sponses. They discovered that combinations may be more
probably to exhibit synergistic effects when targeting on a
negative feedback loop motif or a mutual inhibition loop
motif. As another example, Yin et al. [54] used three-node
enzymatic motifs to study about the synergistic or antag-
onistic interactions within drug combinations considering
different motif topologies and parameters. This study
found that drug combination effects largely depend on
network topology, and the kinetic parameter variations
only yield limited influences on the drug combination
effects. The specific synergistic or antagonistic network
motifs for drug combinations were identified: synergistic
motifs often encompass serial and parallel or mix-type
structures, while antagonistic motifs are mostly with a
positive feedback loop and a downstream link.
Although the pathway or network motif simulation re-
sults may not fully recreate the absolutely real biological
phenomena, considering the network structures of the
pathways which are more inclined to generate synergistic
effects, these models have also come out with some
hypotheses about the synergy mechanism underlying drug
combinations: drugs targeting on certain types of struc-
tures, like cross-talk, parallel or mutual inhibition loop in
pathways will lead to synergistic drug combination effects.
Although these hypotheses may not hold true in all cases,
they can still provide guidance for the rational design of
potentially effective drug combinations. Some studies can
reduce the combinatorial drug screening space by select-
ing drugs with targets on compensatory or inter-linked
pathways [55–57].
However, one limitation of these pathway models is that
we only partially understand the pathways of most dis-
eases or drugs, as pointed out in [58]. With the accumula-
tion of the “omic” data and various reverse engineering
methods [59, 60], more and more disease-specific path-
ways can be reconstructed. These new pathways will pro-
vide more bases for drug synergy mechanism illustration.
However, most of the existing researches focus on the
target-pathway (or motifs) interactions, ignoring other
drug-organism interactions (e.g., drug absorption or me-
tabolism). To obtain a more comprehensive description of
synergy mechanism, future studies should pay more atten-
tion to construction of comprehensive network models
considering not only drug targeting pathways but also
other drug behaviors like absorption, metabolism, trans-
portation, and even toxicity-related pathways.
Computational models based on integrated drug
similarities
In addition to the network-based synergy principles, other
forms of synergy mechanism, which can be owed to cer-
tain chemical or pharmacological properties such as
chemical structure, drug indication, and drug side effects,
should also be characterized. In order to understand drug
synergy from a more global perspective, different types of
drug properties need to be considered simultaneously.
Some computational methods have been proposed to inte-
grate various similarities based on different drug proper-
ties to build classification models for drug combinations.
Drugs or drug combinations can be represented as their
corresponding features described by multiple drug proper-
ties. Thereby different machine learning methods can be
utilized in the prediction or classification for synergistic
drug combinations. For example, Zhao et al. [61] developed
a computational model for the prediction of effective drug
combinations based on the correlations between candidate
combinations and confirmed combinations. In this study,
each drug pair was featured as the pairwise combinations
of their comprehensive molecular and pharmacological
elements, including drug targets and their corresponding
downstream pathways, medical indication areas, Anatom-
ical Therapeutic Chemical (ATC) codes, and side effects.
Based on the enrichment levels of the candidate drug pair
features among all the drug pair features from known drug
combinations, Zhao et al. [61] have predicted novel pair-
wise drug combinations, among them 69 % can be
validated by literature reports. Another research used
Fig. 3 Examples of network motifs in pathways. a. Positive feedforward;
b. Positive feedback; c. Negative feedforward; d. Negative feedback. S
represents stimulus, P1, P2 are proteins in a pathway, and R represents
the effector protein. Different types of the directed edges represent
activation or inhibition effects between two connected elements. For
example, P1 has an activation effect on P2 in Fig. A, while P1 has an
inhibition effect on R in Fig. D. The study of Zhang et al. [53] discovered
that combinations may be more probably to exhibit synergistic effects
when targeting on a negative feedback motif. The study of Yin et al. [54]
found antagonistic drug interactions are mostly related with a positive
feedback loop. This figure is reproduced from [50], with permission from
Elsevier (RightsLink license number: 3687391088768)
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associations of drugs in a combination to describe drug
combination features [62]. Considering three different
kinds of drug relationships including chemical interactions
between drugs in the combination, protein interactions
between the targets of drugs, and target enrichment of
Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathways, each drug combination was represented as a
high-dimensional numeric vector. Then a random forest
classification model was constructed based on the key fea-
tures extracted from high-dimensional numeric vectors to
predict synergistic drug combinations. A 5-fold crossover
validation showed this classification model was well per-
formed with a Matthews correlation coefficient of 0.673.
Prediction or classification models based on properly
selected drug properties can help to identify potential
synergistic drug combination. The most important part
of such computational models is the feature calculation
for drug combinations. Informative features will improve
the prediction accuracy and help to reveal synergy
mechanism. Besides, samples collection is another im-
portant step. Consequently, more efforts should be put
in the elaborate design of effective features for identifica-
tion of drug combinations and collection of drug combi-
nations with or without confirmed synergistic effects.
“Omic”-based methods in synergy identification
With advances in bioinformatics, systems biology and mo-
lecular biology, different types of high-throughput “omic”
data such as genomics, transcriptomics and metabolomics
data have emerged as critical information in the biomed-
ical and pharmaceutical fields [63–65]. The “omic” data
have been widely used in the establishment of interactions
among small molecules, genes and diseases and the identi-
fication of molecules specifically associated with certain
pathological processes [66–69]. Owing to its benefits in
reflecting biological responses, “omic” data has also made
great contributions to drug combination studies. One of
the pioneering studies was the CMAP project by Lamb et
al. [69]. Based on this project, the researchers illustrated
the possibility of rational drug combinations [33, 69].
Considering the aim of “omic” is at collectively quanti-
fying pools of biological molecules [70], specific compu-
tational approaches has also been proposed to predict
the human-body responses to drug combinations or
constructing novel molecular networks based on “omic”
data [33, 71–74].
The most commonly used “omic” data are the gen-
omic data. To reduce the burden in genomic data acqui-
sition for all possible combinations, the corresponding
genomic data for drug combination has been predicted
by computational methods based on the data of individ-
ual ones. Based on this principle, Wu et al. [71] pro-
posed a computational scheme to predict the gene
expression profiles for drug combinations based on gene
profiles treated with individual drugs. Then, according
to the differential expression changes of genes, they ap-
plied a new integer programming model to identify sub-
networks affected by single drugs or combinations from
the background molecular network which included pro-
tein interactions, protein-DNA interactions, and signal-
ing pathways. Finally, the best candidates of combination
drugs were determined by taking into account efficacy
and side-effect based on the identified sub-networks.
The genomic data can also help reconstruct specific mo-
lecular network. As mentioned above, the synergy
ranker: “DrugComboRanker” [33] utilized the genomic
data for drug functional network construction. More-
over, the Petri-net model which is a graph-based math-
ematical method for the description of distributed
systems has also been applied in drug combination ana-
lysis based on the genomic data. Jin et al. [72] proposed
an enhanced Petri-net (EPN) model based on the gene
expression data to simulate drug effects. According to
the EPN model, the synergistic effects of pairwise drug
combinations were identified when there was at least
one molecule that shows an enhanced effect in the com-
bination comparing with the summation effects of two
individual drugs; and the researchers illustrated that the
synergy mechanism was related with the feedback loops
among molecules. Besides, some researchers adopted
correlation-based strategies to calculate the similarities
of “omic”-based responses to drug interventions [73, 74].
Based on the genome-wide expression profiles, Zhao
et al. [73] have revealed the synergistic drug effects by
quantitatively profiling cellular responses to drugs. Ac-
cording to the drug similarities based on a chemoge-
nomic profile, Jansen et al. [74] identified antifungal
synergies. They found that compound pairs that have
correspondingly similar profiles are more likely to be
synergistic when compared with randomly chosen
compounds.
In addition to genomic data, proteomics is another type
of “omic” data for drug synergy study. This type of data
can help reconstruct the signaling pathways. As we have
mentioned in “Dynamic pathway simulation”, the signal-
ing pathways were reconstructed based on the phosphor-
ylation data of key signaling proteins [40–46] by different
pathway simulation methods.
Integration of different types of “omic” data can also
help explore synergy mechanism. By incorporating phos-
phoproteomics, transcriptomics and chemical proteo-
mics data, Winter et al. [75] discovered that the
underlying synergy mechanism for the combination of
danusertib and bosutinib in the treatment of imatinib-
resistant Chronic myelogenous leukemia (CML) might
be related with the nonobvious off target effects impli-
cated in the Mitogen-activated protein kinases (MAPK)
signaling pathway.
Chen et al. BMC Systems Biology  (2015) 9:56 Page 7 of 10
With accumulation of “omic” data, the field of systems
biology has progressed at an even higher speed. The
“omic”-based drug synergy studies are presently mainly
conducted on the genomics and proteomics levels. To
understand the complex interplay of drug combinations
against the disease process, integrative “omic”-based
models covering across various “omic” data like genetic,
transcriptomic, proteomic and metabolomics data need
to be developed.
Conclusion
Rational design of drug combinations with synergistic
effects remains a challenging task despite tremendous ex-
perimental and clinical efforts. Examples presented in this
review illustrate how systems biology approaches are mak-
ing encouraging contributions to explore synergistic drug
combinations. Given the complexity of synergy mechan-
ism and the difficulty in drug combination screening,
systematic synergy modeling will become a very important
component in the field of drug combinations beyond
question. However, there are still great challenges to
overcome.
Network or pathway-based methods have already facili-
tated the prediction of synergistic drug combinations and
promoted the understanding of synergy mechanism.
Based on varied pathway modeling methods and the
increasing “omic” data, pathways for different diseases can
be reconstructed, thus providing firm foundations for the
exploration of synergy. However, mostly focusing on drug
targets to represent drug action, these models for drug
synergy mainly depend on the interaction between targets
and disease-specific network or pathways. Such methods
neglect the fact that synergy can also arise when one drug
increases the effects of other drugs by influencing on their
certain properties like bioavailability as revealed in [76].
Drug behaviors are not simply determined by targets,
other factors like the absorption, distribution, metabolism,
and excretion (ADME) processes and off-target activities
can also have significant impacts on drug therapeutic out-
comes. Even though some classification models based on
integrated drug features considering comprehensive
chemical and pharmacological properties have overcome
this “target-only” issue; however, the current number of ef-
fective drug combinations and their obtainable properties
will limit the performance. Consequently, more attention
should be paid on the acquisition and integration of ex-
tensive knowledge to model the drug-organism interplay.
Systems biology models for drug synergy evaluation are
still in their infancy, but have shown prominent advan-
tages in exploring synergistic drug combinations. The
potential synergy mechanism has also been illustrated
based on these methods. To understand drug synergy
from a more comprehensive perspective, future efforts
should be put on novel approaches which can model the
synergistic effects from a more holistic perspective cover-
ing across pharmacology-considering both pharmaco-
dynamics and pharmacokinetics elements-and toxicology
spaces. With a deep insight into drug synergy, systems
biology approaches will serve as a compensative tool for
the rational design of effective drug combinations.
However, it should also be noted that systems biology
modeling is only an aided tool but not the judge. The drug
synergy predictions can provide valuable references for
experimental drug combination screening, but they can-
not substitute the experimental methods to determine the
final statement on drug synergism or antagonism. The
systematic synergy modeling methods can provided assis-
tances for drug synergy researches, but the effectiveness
and accuracy of these predictive models should still rely
on experimental evaluations.
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